Sonrotoclax (Beqalzi), a Bcl-2 inhibitor, won FDA approval in May 2026 for mantle cell lymphoma patients who have tried at least two prior therapies. The approval adds only the second Bcl-2 inhibitor option in the U.S., with Beqalzi framed as rationally designed to enhance potency against both wild-type and mutant Bcl-2. The approval is expected to set up further label growth efforts as ongoing trials look to confirm early clinical results and potentially broaden the treatment scope. The therapy’s position will be monitored against venetoclax as the market works through sequencing and combination strategies. For hematology teams, the practical question will be how soon real-world uptake follows reimbursement and how quickly clinicians test the new agent across prior-therapy strata. The release also reinforces that small-molecule mechanism differentiation in apoptosis pathways continues to matter as companies look for incremental advantages in survival, safety, and tolerability.